Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

ABSTRACT:

Background

Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited.

Methods

In a phase 3 trial, we randomly assigned (in a 2:1 ratio) patients 70 years of age or younger with previously untreated CLL to receive either ibrutinib and rituximab for six cycles (after a single cycle of ibrutinib alone), followed by ibrutinib until disease progression, or six cycles of chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The primary end point was progression-free survival, and overall survival was a secondary end point. We report the results of a planned interim analysi

SUBMITTER: Shanafelt TD 

PROVIDER: S-EPMC6908306 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature